SPDR S&P Biotech ETF (SSGF)
XBER 
Summary
SSGF Chart
Should You Invest in the State Street SPDR S&P Biotech ETF (XBI)?
Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the State Street SPDR S&P Biotech ETF (XBI), a passively managed exchange traded fund launched on January 31, 2006.
Wall Street Technician Declares Financials, Industrials, and Biotech Poised for Breakouts. 3 ETFs Could Soar.
Markets are hunting for new leadership as the Big Tech engine sputters, and one Wall Street technician thinks she knows where the baton is being passed.
XBI: A "Hidden" ETF Up +70% In 1 Year.
State Street SPDR S&P Biotech ETF (XBI) has delivered over 75% 1-year performance, driven by equal-weight exposure to volatile small- and mid-cap biotech stocks. XBI's high beta profile offers strong upside in bullish healthcare cycles but exposes investors to elevated annualized volatility of around 26%. Current valuations for XBI are relatively stretched, with forward P/E at 17x and earnings growth expectations below 3%, making new entry less attractive.
SPDR S&P Biotech ETF (SSGF) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has SPDR S&P Biotech ETF ever had a stock split?
SPDR S&P Biotech ETF Profile
| XBER Exchange | US Country |
Overview
The provided company is a financial entity that focuses on mirroring the performance of the S&P Biotechnology Select Industry Index. By employing a sampling strategy, the fund aims to invest predominantly, if not entirely, in the components that make up the index. This index is a representation of the biotechnology segment of the S&P Total Market Index (S&P TMI), encompassing companies within the biotechnology industry. The strategy includes investing at least 80% of its total assets in the securities that form part of the index, ensuring a strong alignment with the biotechnology sector's market movements.
Products and Services
- Biotechnology Industry Index Fund
This product is designed for investors seeking exposure to the biotechnology sector. The fund tracks the S&P Biotechnology Select Industry Index, which is a subset of the larger S&P Total Market Index (S&P TMI) focused specifically on the biotechnology industry. By putting a significant portion of its assets—substantially all, but at a minimum, 80%—into the securities that compose the index, the fund offers a direct pathway for investment in a diversified portfolio of biotechnology companies. The sampling strategy employed aims to replicate the index's performance, making it an attractive option for those looking to invest in the biotechnology industry through a mechanism that mirrors its market dynamics closely.
